More time is now spent on the Internet through smartphones than on PCs; that includes both work and leisure time. But it’s not necessarily easier to connect with your customers.
Investors got their chance to dive a little deeper into Biogen’s finances at its third-quarter 2016 conference call. Despite a pop in the stock value and some promising news for nusinersen and aducanumab, there are other factors that make Biogen seem like a company in pause mode waiting for something to happen.
Genomic company 23andMe halted its plans to develop a new gene-sequencing program that would have allowed customers to learn more about potential predisposition to genetic diseases.
Sanofi struck a collaboration deal with a leading Brazilian research institute to speed development of a Zika vaccine, consolidating the French drugmaker’s position in the race to defeat the mosquito-borne virus.
People who live through a bout with cancer are more likely to use medication for anxiety and depression than those without a history of malignancies, a U.S. study suggests.
Health authorities in Colombia and Brazil will launch large-scale mosquito-control campaigns using a using naturally occurring bacteria known as Wolbachia.
Privately held drugmaker Kaleo Inc. announced plans for a U.S. relaunch of its Auvi-Q injector for life-threatening allergic reactions in the first half of 2017.
When Novartis shuttered its five-year-old Cell and Gene Therapy Unit in August, it sent shockwaves through the CAR-T community as some believed it to be a signal the company was abandoning the immuno-therapy research program for good. This, despite the company saying on several occasions that the move was not an end of CAR-T at the Swiss company, but merely part of a restructuring process that would be more cost efficient. That was something Novartis Chief Executive Officer Joe Jimenez recently reiterated during a conference call with investors.
With many biopharma companies reporting their third-quarter financials, there is often an inevitable question – What’s your merger-and-acquisition strategy? Both Merck and Novartis faced this question. Here’s what their chief executives had to say.